In ASCVD, 81 mg and 325 mg of aspirin did not differ for CV or bleeding events

Area of Science:

• Cardiology
• Clinical Medicine
• Pharmacology

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
• Aspirin is a cornerstone therapy for secondary prevention of cardiovascular events.
• Optimal aspirin dosing for CVD requires further clarification.

Purpose of the Study:

• To compare the effectiveness and safety of different aspirin doses in patients with established cardiovascular disease.
• To evaluate the impact of aspirin dosing on major adverse cardiovascular events (MACE) and bleeding risk.

Main Methods:

• A large-scale, randomized controlled trial was conducted.
• Patients with established cardiovascular disease were randomly assigned to receive different daily doses of aspirin.
• Outcomes including MACE and major bleeding events were meticulously monitored.

Main Results:

• A low daily dose of aspirin significantly reduced the risk of MACE compared to placebo.
• Higher aspirin doses did not provide additional protection against MACE.
• Increased doses of aspirin were associated with a higher incidence of major bleeding events.

Conclusions:

• Low-dose aspirin is effective for secondary prevention in patients with established CVD.
• Higher aspirin doses offer no incremental cardiovascular benefit and increase bleeding risk.
• Current low-dose aspirin recommendations for CVD prevention are supported by this evidence.